Loading…
Loading…
INIS does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for INIS and 80,000+ other tickers.
See exactly how INIS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for INIS and 80,000+ other tickers.
Radnostix, Inc. (INIS) is a company that specializes in the global manufacturing and sale of crucial nuclear medicine calibration and reference standards, cobalt-60 products, and offers contract services for producing radiopharmaceuticals and radiochemicals. Its operations are structured into five key divisions: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products. The Nuclear Medicine Standards segment is responsible for creating various sources and standards essential for single photon emission computed tomography (SPECT) and…
IDAHO FALLS, Idaho, Aug. 13, 2026 /PRNewswire/ -- Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB: INIS) ("Radnostix" or the "Company"), a manufacturer of radioisotope-focused technologies for medical, industrial, and research applications, today announced its financial results for the second quarter and six months ended June 30, 2026 and the filing of its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission. Second Quarter and First Half 2026 Financial and Operational Summary Total revenue for the three months ended June 30, 2026 was $2.67 million, a 27% decrease from $3.66 million in the prior-year period.
IDAHO FALLS, Idaho, July 2, 2026 /PRNewswire/ -- Radnostix, Inc. (OTCQB: INIS) ("Radnostix" or the "Company"), a leader in radioisotope production and nuclear medicine solutions, today announced the successful closing of its acquisition of key assets from Lucerno Dynamics, LLC, including the LARA® System technology platform, ELLEXA® Explorer software and associated intellectual property. The product line was originally developed to identify, improve dosimetry of, and reduce the frequency of extravasations of IV administered radiopharmaceuticals.
IDAHO FALLS, Idaho, May 21, 2026 /PRNewswire/ -- Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB: INIS) ("Radnostix" or the "Company"), a manufacturer of radioisotope-focused products for medical, industrial, and research applications, today announced its financial results for the first quarter ended March 31, 2026 and the filing of its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission. First Quarter 2026 Financial and Operational Summary Total revenue decreased 27% to $2.38 million from $3.24 million in the first quarter of 2025, driven by recall impacts, isotope shortages, and Co60 down time.
IDAHO FALLS, Idaho, April 1, 2026 /PRNewswire/ -- Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB: INIS) ("Radnostix" or the "Company"), a leading manufacturer of radioisotope-focused technologies for medical, industrial, and research applications, today announced its fiscal year 2025 financial results and corporate updates. Fiscal 2025 Highlights Total revenue reached $13.07 million, the second-highest annual revenue in Company history, reflecting healthy demand across core segments despite targeted supply chain challenges.
International Isotopes Inc. (OTCMKTS:INIS - Get Free Report)'s share price passed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $0.07 and traded as low as $0.0690. International Isotopes shares last traded at $0.07, with a volume of 101,261 shares trading hands.